9 results about "SH3 domain" patented technology

The invention discloses a function and an application of a fish LIM and SH3 structural domain protein 1 (LASP1) gene in fish antiviral immune regulation, and particularly discloses a molecular mechanism and an application value of the LASP1 as an immune negative regulation factor in carassius auratus herpesvirus (CaHV) infection. Experiments prove that fish LASP1 has the function of remarkably inhibiting immune regulation generated by host interferon and can promote CaHV proliferation for the first time, and knock-down of the gene can effectively enhance host antiviral response and inhibit CaHV infection. Therefore, the lasp1 gene can be used as a new target for preventing and treating CaHV infection, is used for preparing a preparation for preventing or treating CaHV infection, or is used for gene editing of a cell model for preventing CaHV infection or a new crucian carp variety.

The present invention is directed to SH3 domain derivatives having a specific binding affinity to a target molecule. In this respect, the invention provides SH3 domain derivatives of nephrocystin (NPHP1) and the Tec kinase. The invention also provides a method for the production of a library comprising recombinant derivatives of NPHP1 or the Tec kinase SH3 domains and a method for selecting from the library one or more derivatives of the SH3 domain of nephrocystin (NPHP1) or the Tec kinase having a specific binding affinity to a target molecule.

The present invention relates to using c-Src SH3 RT-loop as a target for anti-thrombosis. Specifically, the present invention provides the use of a c-Src SH3 RT-loop antagonist for preparing a composition or preparation, and the composition or preparation is used for: (a) interfering with the interaction between integrin β3 and c-Src; (b) inhibiting platelet spreading on solid-phase fibrinogen; (c) inhibiting platelet aggregation and / or adhesion; and / or (d) preventing and / or treating thrombosis. The present invention discovers for the first time that a drug combination or preparation targeting the RT-loop region of the c-Src SH3 domain can effectively treat thrombotic diseases without increasing the risk of bleeding.

The application discloses an axSpA diagnosis biomarker combination and application thereof in judging axSpA diagnosis effect, relates to the biomedical field, and comprises the following four plasma proteins: LIM and SH3 domain protein 1 (LASP1), calponin binding protein 2 (CNN2), neuron protein kinase C and tyrosine protein kinase substrate 2 (PACSIN2) and tropomyosin 4 (TPM4). The expression levels of the four proteins in the plasma of axSpA light / severe group patients are all up-regulated relative to a healthy control group, and there is a significant difference between the severe group and the light group. Through deep proteomics, multi-algorithm statistics, machine learning models and independent queue immunological verification, the protein combination composed of LASP1, CNN2, PACSIN2 and TPM4 is first systematically identified and verified as an excellent performance of axSpA diagnosis biomarker.

The present invention relates to a compound for treating thrombotic diseases. Specifically, the present invention provides a compound represented by formula I, or a pharmaceutically acceptable salt, or an enantiomer, or a diastereoisomer, or an atropisomer, or a racemate, or a polymorph, or a solvate, or an isotopically labeled derivative thereof. The compound disclosed in the present invention can be specifically combined with SH3 domain protein of Src kinase and then interfere the combination of integrin αIIbβ3 and Src kinase, so that outside-to-inside signal transduction is selectively inhibited and inside-to-outside signal transduction is not influenced; thus, while resisting thrombus, the compound of the present invention does not affect the normal physiological hemostatic function, prevents the occurrence of hemorrhagic side effect, and can be used as a new generation of effective medicine for preventing and treating thrombosis-related cardiovascular and cerebrovascular diseases.

This invention relates to a compound for treating thrombotic diseases. Specifically, this invention provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, or its enantiomer, diastereomer, transtransferase, racemic mixture, polymorph thereof, solvate thereof, or isotopically labeled derivative thereof. The compound of this invention specifically binds to the SH3 domain protein of Src kinase, interfering with the binding of integrin αIIbβ3 to Src kinase, thereby selectively inhibiting outward-to-inward signal transduction without affecting inward-to-outward signal transduction. This allows the compound of this invention to exert antithrombotic effects without affecting normal physiological hemostasis, avoiding bleeding side effects, and thus becoming a new generation of effective drugs for the prevention and treatment of thrombosis-related cardiovascular and cerebrovascular diseases.

A method of identifying a lead or candidate compound that modulates the activity of GTPase-Activating Protein SH3 Domain-Binding Proteins (G3BP) is provided, which includes determining whether a compound modulates the interaction between the N-terminal Nuclear Transport Factor 2-like (NTF2L) domain of G3BP and FGDF peptide of ubiquitin specific protease 10 (USP10) or non-structural protein 3 (nsP3).

This invention discloses a recombinant *Escherichia coli* strain that synergistically enhances the synthesis efficiency of β-elemene based on liquid-liquid phase separation, temporal regulation, and dynamic multi-enzyme assembly, and its application in β-elemene biosynthesis. In the recombinant *E. coli* strain, a stable covalent dual-enzyme complex of IspA and GAS is first constructed using a SnoopTag / SnoopCatcher system, and the upstream key enzyme IDI is further introduced. Simultaneously, the RGGRGG repeat sequence, capable of forming membrane-free droplets, is used as a phase separation scaffold, with an SH3 ligand fused to its N-terminus. The SH3 domain is then linked to the C-terminus of both the IspA-GAS enzyme complex and IDI. Through the specific interaction of the SH3 ligand / SH3 domain, the key enzyme is directionally recruited and spatially enriched into the aggregates. A temporal regulation strategy is also introduced: the expression of the IspA-GAS enzyme complex and IDI is first induced by IPTG, followed by delayed induction of RGGRGG aggregate expression, thus recruiting the already formed enzyme complex into the aggregates. This invention not only reduces the amount of glycerol used and improves the glycerol conversion rate, but also increases the yield of β-elemene.

The present invention relates to a composition for enhancing the anticancer effect of sorafenib, comprising a SASH1 overexpression vector as an active ingredient. The composition comprises a polynucleotide sequence for inducing the overexpression of SASH1 (SAM and SH3 domain-containing protein 1) comprising a sequence commonly expressed by isoforms of a SASH1 gene. Since the vector of the present invention has an excellent anticancer effect by itself while increasing the anticancer effect of sorafenib, the composition comprising the SASH1 overexpression vector and / or sorafenib as an active ingredient can be usefully used as a substance for preventing or treating cancer.